Showing results (631-640 of 658) with videos related to
Sort By:
Pageof 66
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2020
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001Paul D Brown, Vinai Gondi, Stephanie Pugh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade GliomaErica H Bell, Peixin Zhang, Edward G Shaw, et al.Neuro-Oncology|April 28, 2025
Establishing the content validity of Patient-Reported Outcome measures used in neuro-oncology based on the WHO ICF framework: part of the RANO-PRO initiativeOgechukwu A Asogwa, Linda Dirven, Tobias Walbert, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Central nervous system cancersLouis Burt Nabors, Mario Ammirati, Philip J Bierman, et al.The New England Journal of Medicine|June 29, 2022
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine GliomaJaime Gállego Pérez-Larraya, Marc Garcia-Moure, Sara Labiano, et al.Nature Medicine|May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled TrialByram H Ozer, Scott M Lindhorst, Ryan T Merrell, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Central nervous system cancers, version 2.2014. Featured updates to the NCCN GuidelinesLouis Burt Nabors, Jana Portnow, Mario Ammirati, et al.Science Translational Medicine|October 8, 2025
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analysesAlexander L Ling, Jennifer Gantchev, Michael C Prabhu, et al.Neuro-Oncology|July 18, 2022
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trialAndrew B Lassman, Stephanie L Pugh, Tony J C Wang, et al.Pageof 66